JonesResearch analyst Debanjana Chatterjee upgraded Spyre Therapeutics (SYRE) to Buy from Hold with a $64 price target The company reported positive data from the Phase 1 healthy volunteer trial of SPY003, the analyst tells investors in a research note. Ahead of updates in 2026, the firm believes the stock’s risk/reward “now skews positive.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics: Promising Innovations and Strong Financials Justify Buy Rating
- Spyre Therapeutics Reports Q3 2025 Financial Results
- Spyre Therapeutics reports Q3 EPS (15c), consensus (74c)
- Spyre Therapeutics Reports Positive Phase 1 Results for SPY003
- Spyre Therapeutics Advances in Ulcerative Colitis Treatment Study